IMRA News and Press, IMARA Inc. From 03/29/21

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that applications ...

The following slide deck was published by IMARA Inc. in conjunction with this event. For further details see: IMARA (IMRA) Investor Presentation - Slideshow

Imara (IMRA) announces that separate independent data monitoring committees ((DMCs)) for the Ardent and Forte Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia have recommended opening of the higher dose IMR-687 treatment arm in each of these studies following r...

Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses Safety Review Committee in Phase 2a open label extension trial supports dail...

Imara, Inc. (IMRA) Q4 2020 Earnings Conference Call March 05, 2021, 08:30 ET Company Participants Michael Gray - CFO & COO Rahul Ballal - President, CEO & Director Conference Call Participants Matthew Harrison - Morgan Stanley Kelly Girskis - SVB Leerink Presentation Operator Ladies a...

Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Innovation (PRPL) +19%.Plus Ther...

Imara shares slide ([[IMRA]] -18.6%) after the company reported full-year results and provided financial forecast for 2021.Net loss was $49.2M, or $3.53/share, for the year ended December 31, 2020, compared to a net loss of $23.5M, or $33.40/share last year.Research and development expenses w...

Imara (IMRA): FY GAAP EPS of -$3.53 misses by $0.27.Cash, cash equivalents and investments of $88.2M.FY21 guidance:  Research and development expenses in the range of $50M-55M; general and administrative expenses in the range of $12M-14M.Press Release For further details see: ...

Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical trial data Company to host conference call and live webcast today at 8:30...

BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wi...